Theriva Biologics, Inc. Annual Report: Fiscal Year 2023 Review

This summary provides an overview of Theriva Biologics' (TOVX on the NYSE American exchange) annual report for the fiscal year ended December 31, 2023. It offers key insights into the clinical-stage biopharmaceutical company's operations and financial standing.

Business Overview: What Theriva Biologics Does Theriva Biologics develops novel treatments, primarily for infectious diseases and neurological disorders. The company aims to bring new therapies to market by advancing its drug candidates through clinical trials. As a clinical-stage biopharmaceutical company, its main activities involve research, development, and clinical testing of these drug candidates.

Financial Performance for 2023 As a company in the development phase, Theriva Biologics reported just $0.2 million in revenue for the year, mainly from grants or collaborations. With a strong focus on research and development, the company reported a net loss of $28.5 million for the fiscal year. Key expenses included $20.1 million in research and development (R&D) to advance its drug candidates.

Risk Factors: Key Considerations for Investors Investing in a clinical-stage biotech company like Theriva Biologics involves significant risks that investors should understand:

• Clinical Trial Success: The company cannot guarantee the success of its drug candidates, and trials can fail at any stage, severely impacting the company.
• Funding Needs: As highlighted by its cash runway, the company will require substantial additional capital to complete development and commercialization. This often leads to future stock dilution through new share offerings.
• Regulatory Approval: Obtaining FDA or other regulatory approvals is a complex, lengthy, and uncertain process, even with positive clinical data.
• Competition: The biopharmaceutical industry is highly competitive. Other companies may develop more effective or cheaper treatments.
• Liquidity: The low trading volume typical of micro-cap stocks can make it difficult to buy or sell shares without significantly impacting the price.
• Reliance on Third Parties: The company often relies on contract research organizations (CROs) and contract manufacturing organizations (CMOs) for clinical trials and drug production, which introduces risks related to their performance and compliance.

Financial Health: Cash Position, Debt, and Liquidity As of December 31, 2023, the company reported $12.3 million in cash and cash equivalents. At its current spending rate, this cash provides an estimated runway of approximately 5 to 6 quarters. Therefore, Theriva Biologics will likely need to secure additional funding within the next 12-18 months to continue operations and advance its clinical programs.

Future Outlook Looking ahead, Theriva Biologics will primarily focus on continuing clinical development of its lead drug candidates, aiming to complete ongoing trials, initiate new studies, and generate compelling data. It expects significant ongoing investment in research and development. Management plans to seek strategic partnerships or collaborations to accelerate development and commercialization, and explore financing options to extend its cash runway and support its pipeline. The ultimate goal is to bring novel therapies to market, pending successful clinical outcomes and regulatory approvals.

Competitive Position The biopharmaceutical industry is intensely competitive. Theriva Biologics operates in therapeutic areas with many competitors, including large pharmaceutical companies, biotechnology firms, and academic institutions. Many competitors possess significantly greater financial, technical, and human resources, along with more extensive experience in clinical testing, regulatory processes, manufacturing, and marketing. Competition comes from existing approved therapies and new products under development. Theriva Biologics aims to differentiate its drug candidates by their novel mechanisms of action and potential to address unmet medical needs.

Understanding Its Size: A Micro-Cap Company Theriva Biologics is a "Smaller Reporting Company," categorized as a micro-cap. As of March 15, 2024, with approximately 45.9 million shares outstanding and a stock price of about $0.43 per share, its market capitalization was roughly $19.7 million. This small size often makes its stock more volatile and sensitive to news, presenting both higher potential risks and rewards for investors.

Forward-Looking Statements: Like many development-stage companies, this report contains "forward-looking statements" about future plans and expectations. However, these statements are subject to various risks and uncertainties, meaning actual results could differ significantly from the company's expectations.